A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

Summary

RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)

Timeline

Start

2023-08-31

Primary completion

2024-11-29

Completion

2025-05-30

Outcome

Met primary endpoint

release “The trial achieved its primary endpoint of the mean change from baseline in DAS-28 CRP at Week 12 for all three doses of rosnilimab” anaptysbio.com ↗

release “Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS28-CRP score across all three rosnilimab doses vs. placebo” anaptysbio.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rosnilimab	Monoclonal antibody	—	Subcutaneous

Indications